Increasing evidence recently confirmed EP’s anti-tumor activities via apoptosis-promoting pathways or anti-angiogenic pathways, targeting JAK2/STAT3 signals in human hepatocellular carcinoma cells (Hep3B and HepG2), human prostate cancer cells (LNCaP and DU-145 cell lines), and human multiple myeloma U266 cells [13,14,15,25]. This evidence concerns the gene JAK2 and prostate cancer.